Nivolumab alone or in combination with ipilimumab are promising treatment options for patients with mucosal melanoma, according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18–21 in San Francisco.
Conferences
Immune Expression in Sentinel Lymph Node Biopsies Helps Predict Melanoma Outcomes
The expression of immune markers and T-cell subsets can help predict outcomes of sentinel lymph node (SLN)-positive melanoma patients, according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18–21 in San Francisco.
Melanoma Patients Suffer Side Effects of Checkpoint Inhibitors, Yet Maintain QoL
Advanced melanoma patients successfully treated with a combination of nivolumab and ipilimumab may endure severe side effects, but they do not suffer any clinically meaningful changes in health-related quality of life (QoL), according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18–21 in San Francisco.
Immune Boost May Lower Risk for Melanoma Recurrence
Results from two small clinical trials have shown that intradermal injection of the immune system–boosting agent CpG-B after surgery can reduce the recurrence risk for stage I/II melanoma. The study was presented at the 2015 International Cancer Immunotherapy Conference (abstract A050)